UCLA uses new device to replace aortic valve in patients who
can't have open-heart surgery
UCLA has performed its first transcatheter aortic valve
replacement (TAVR), using a new device approved by the U.S. Food and Drug
Administration to replace an aortic valve in a patient who was not a candidate
for open-heart surgery. The procedure took place on Aug. 9.
Ronald Reagan UCLA Medical Center is part of a growing trend
of hospitals nationwide offering this new minimally invasive procedure.